关于试验终止，在NMPA GLP规范里有这样的描述：
第二十八条 研究被取消或者终止时，试验方案变更应当说明取消或者终止的原因和终止的方法。
第三十二条 研究被取消或者终止时，专题负责人应当撰写简要试验报告。
第四十二条 研究被取消或者终止时，专题负责人应当将已经生成的上述研究资料作为研究档案予以保存归档。
第四十五条 档案的保存期限应当满足以下要求：
（二）未用于注册申报材料的研究（如终止的研究），其档案保存期为总结报告批准日后至少五年；
上面只说了试验要怎么处理，但是没有说能不能转为非GLP来终止。
关于这个问题，在WHO GLP handbook中有如下描述：
It is not acceptable to claim GLP compliance for a non-GLP study after it has started. If a GLP-designated study is continued as a non-GLP study, this must be clearly documented.
非GLP试验在开始后不能转为GLP试验；如果GLP试验转为非GLP必须清楚记录。
也就是说WHO认为可以，即使他没有明说是为什么转为非GLP的。
但是，在OECD第21号文件中有更明确的表述：
A sponsor may decide to terminate the study in progress before it has concluded.
The early termination of a study may occur prior to, or after, the completion of the experimental phase of the study, but before the data has been assessed or incorporated in a final report. In both situations, a study plan amendment must be produced in order to provide an explanation of why the study was terminated. Some compliance monitoring authorities may expect that the key findings up to the point of termination are summarised and that the summary report is subject to a QA audit. To ensure the termination of the study is done in a controlled and transparent way, the test facility should retain communications from the sponsor that justify the decision to stop the study. The same process about documentation should apply when the sponsor asks for a GLP study to be changed to a non-GLP study. Terminated studies and studies for which the requested status changed from GLP to non- GLP should be indicated as such in the master schedule.
翻译：
委托方可能会在试验已经有结论前就终止试验。
终止试验可能在数据评估和整合之前或者之后发生，两种情况下，都应该出具试验方案变更以解释说明为什么试验被终止。一些监管机构可能希望试验终止前的关键发现被总结，且总结报告交由QA进行审核。
为保证试验的终止是受控且透明的，试验机构应保存和委托方证实终止试验决定的沟通记录。当委托方要求从GLP试验转为非GLP试验时，也应如此。
终止的和转化为非GLP的试验应在主计划表中体现。
上面说到交由QA进行审核，那就是要按照GLP的要求来终止了。
但是，文中也说，是“一些监管机构”，而是哪些监管机构没有说（可能也不方便说）。
其他参考资料：
在文章：Differences in the interpretation of the GLP requirements by OECD monitoring authorities: the point of view from the pharmaceutical industry中，作者-赛诺菲的GLP专家Raymond K. Lowing （GLP质量与合规，赛诺菲-安万特研究与开发，Chilly-Mazarin，法国）提出：
Premature termination of a study due to the development of the compound being stopped (terminated study reports)
Once again, there are major differences between the expectations of the MAs in such situations. Such differences concern the type of reports which need to be produced, the involvement of the QA staff and the GLP status of such studies. A number of MAs do not consider it unusual, following suitable study plan amendments with adequate explanations, that the study be stopped and that the laboratory does not waste time on any unnecessary work either by the operational staff or by the QA staff. Since not all aspects of the initial plan were completed, then the study can be downgraded to non-GLP compliant. FDA, however, has the completely opposite point of view in that firstly the study cannot have its GLP status downgraded. It must remain as a GLP compliant study. A study report of some kind must be prepared and the QA personnel must review the report. Other MAs have a third option where they have no objection to the study being downgraded, but a report must be produced which includes a summary of the results obtained. It is difficult to understand these differences among the expectations.
翻译：
由于化合物的开发被停止而过早终止研究(终止研究报告)
在这种情况下，监管机构的预期再次出现重大差异。这些差异涉及需要生成的报告类型、QA人员的参与以及此类研究的GLP状态。在适当的试验方案变更并给出充分的解释之后，许多监管机构认为停止研究，实验室不浪费时间在操作人员或QA人员的任何不必要工作上并不罕见。由于不是所有方面的初步计划都完成了，那么研究可以降级为非GLP。然而，FDA却持完全相反的观点：首先，该研究不能降低GLP水平。它必须作为一个符合GLP的研究。必须准备某种类型的研究报告，QA人员必须审查报告。其他监管机构有第三种选择，他们不反对将研究降级，但必须编制一份报告，其中包括所获得结果的摘要。很难理解这些期望之间的差异。
作者说的很实在，把降级处理的好处都说出来了，还明白指出OECD不方便说的监管机构可能就包括FDA。
在美国某CRO公司网站上找到的信息也应该印证了FDA的要求：
（网页链接及公司信息：
The most expensive study is one you have to repeat. 10 things to know before you start your GLP study. - GCMI Atlanta - Pre Clinical CRO
https://gcmiatl.com/2019/11/19/10-things-to-know-before-starting-a-glp-study/
GCMI---The Global Center for Medical Innovation
575 14th St NW, Atlanta, GA 30318佐治亚州亚特兰大，第14街西北575号，邮编30318）
网页内容：
6. Everything in a GLP study is subject to audit and reporting.
You can’t turn a GLP study into a non-GLP study if it does not appear to be going well. Even if you are not submitting to the regulatory body, the CRO is obligated by law to create an executive summary at minimum to close the study and archive it.
翻译：
如果GLP研究进展不顺利，你也不能把它变成非GLP研究。即使你没有提交给监管机构，CRO也有义务根据法律至少创建一份执行摘要来关闭研究并将其存档。
综上，最稳妥的方法肯定就是把GLP试验按GLP试验来终止，而不是转为非GLP。
如果不是递交给FDA，那可能可以试试转为非GLP试验来省时省力地终止。
但是，也不好确定“一些监管机构”除了FDA之外是不是还有其他的。
所以，如果想转为非GLP来省时省力，最好提前确认一下是否符合监管机构要求。
延伸阅读
